Cover Image
close this bookSources and Prices of Selected Drugs and Diagnostics for People Living with HIV/AIDS (UNAIDS, 2001, 36 p.)
close this folderInformation on sources and prices of selected drugs and diagnostics
close this folder1. Antiretroviral drugs
View the document(introduction...)
View the document1.1 Antiretroviral drugs used in prevention of MTCT and included in MEDL (1999)
View the document1.2 Antiretroviral drugs not included in MEDL (1999)
View the document1.3 Donations and price reductions for antiretroviral drugs

1.1 Antiretroviral drugs used in prevention of MTCT and included in MEDL (1999)

Zidovudine (ZDV, also known as AZT)

Zidovudine is a nucleoside reverse transcriptase inhibitor. It was added to the tenth MEDL solely for use in the prevention of mother-to-child transmission of HIV. However, zidovudine is also used in combination therapy to suppress the replication of HIV. Generic versions are widely available, as 100 mg and 250 mg capsules. The dosage used in prevention of MTCT is usually 300 mg. Indicative prices vary widely depending on the country of origin.

Use in HIV/AIDS: Prevention of MTCT (MEDL). Combination therapy to suppress replication of HIV.

Notes in 11th Model list: Limited indications or narrow spectrum of activity.

- capsule, 100 mg. MEDL. Reported shelf-life: 24 to 60 months
- capsule, 250 mg. MEDL. Reported shelf-life: 48 to 60 months
- injection, 10 mg/ml in 20-ml vial. MEDL. Reported shelf-life: 12 months
- oral solution, 50 mg/5 ml. MEDL. Reported shelf-life: 18 to 24 months
- oral syrup, 10 mg/5 ml. Strength not in MEDL
- tablet, 300 mg. Not in MEDL. Used in pilot projects for prevention of MTCT. Provided as a donation by Glaxo Wellcome to a restricted number of countries.

Nevirapine (NVP)

Nevirapine is a non-nucleoside reverse transcriptase inhibitor. This drug, used in combination therapy to suppress the replication of HIV, was included in the 1991 MEDL for the same indication as zidovudine (prevention of MTCT). For this indication, a combination of tablet for the mother and syrup formulation for the newborn child is required. The indicative cost per treatment is US$ 4 from the patent holder. However, the patent holder, Boehringer Ingelheim, has recently stated that the company will make the product available for MTCT free of charge to the least developed and low-income developing countries with specific programmes for the prevention of MTCT. Countries should approach the company directly for inclusion in this donation. The donation is exclusively for use in the prevention of MTCT* and may not be used in combination therapy to suppress the replication of HIV.

* Use of Nevirapine for the Prevention of Mother-to-Child Transmission of HIV. Technical Notes. WHO HIV/AIDS-RHR-EDM, Geneva, 2001 (WHO/HIV-AIDS/2001.3; WHO/RHR/01.21).

Use in HIV/AIDS: Prevention of MTCT (MEDL). Combination therapy to suppress replication of HIV.

Notes in 11th Model list: Limited indications or narrow spectrum of activity.

- tablet 200 mg. MEDL.
- oral solution 50 mg/ml (240 ml). MEDL.